What is the current revenue of the gastroretentive drug delivery systems market?

The market size of gastroretentive drug delivery systems in 2027 is calculated to be USD 18.5 billion.

What are the growth projections for the gastroretentive drug delivery systems industry?

Gastroretentive Drug Delivery Systems Market size was worth USD 17.6 billion in 2026 and is poised to grow at a 6.08% CAGR between 2027 and 2036, reaching USD 31.76 billion by 2036.

How is the rising burden of gastric disorders influencing demand for gastroretentive drug delivery systems?

Increasing prevalence of gastric-related conditions is driving demand for prolonged-release therapies that maintain drug action in the stomach, improving symptom control, dosing convenience, and treatment reliability compared to conventional oral forms.

How are controlled-release technologies and personalization trends shaping product development priorities?

Advances in floating, mucoadhesive, and expandable systems are improving gastric retention and bioavailability, while personalized formulations are expanding innovation for age-specific needs and enhancing adherence-driven treatment outcomes.

Which type leads the gastroretentive drug delivery systems market?

Floating Drug Delivery Systems led with a 49.82% share in 2026 due to their established role in extending gastric residence time and their broad adoption across relevant formulation and therapeutic applications.

Which distribution channel is growing fastest in the gastroretentive drug delivery systems market?

Online Pharmacies are the fastest-growing distribution channel as patients increasingly prefer digital ordering and home delivery for convenient access to prescribed therapies during longer treatment cycles.

Why does North America lead the gastroretentive drug delivery systems market?

North America leads with 43.78% share due to advanced pharmaceutical R&D infrastructure, strong formulation capabilities, and high adoption of controlled-release drug delivery systems.

What is supporting Asia Pacific growth in this market?

Asia Pacific is growing at 7.35% CAGR, supported by rising pharmaceutical manufacturing capacity and increasing adoption of advanced oral drug delivery technologies.

Which companies are driving growth in the gastroretentive drug delivery systems landscape?

Major companies in the gastroretentive drug delivery systems market include Catalent Inc. (United States), Lonza Group AG (Switzerland), Evonik Industries AG (Germany), AptarGroup Inc. (United States), Colorcon Inc. (United States), Quotient Sciences Limited (United Kingdom), Aenova Holding GmbH (Germany), Ashland Inc. (United States), Vectura Group Ltd (United Kingdom), Evotec SE (Germany).